IRIS
GRAGNANO, Felice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.010
EU - Europa 1.586
AS - Asia 423
AF - Africa 11
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 4.043
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.994
IE - Irlanda 773
IT - Italia 253
SG - Singapore 206
GB - Regno Unito 179
CN - Cina 145
DE - Germania 93
FR - Francia 70
GR - Grecia 53
UA - Ucraina 47
FI - Finlandia 31
SE - Svezia 31
BE - Belgio 22
TR - Turchia 18
IN - India 17
CA - Canada 12
KR - Corea 11
EG - Egitto 8
ES - Italia 8
HK - Hong Kong 8
NL - Olanda 6
BR - Brasile 5
LT - Lituania 4
TW - Taiwan 4
AU - Australia 3
CZ - Repubblica Ceca 3
EU - Europa 3
MX - Messico 3
PK - Pakistan 3
PL - Polonia 3
AR - Argentina 2
AT - Austria 2
ID - Indonesia 2
JP - Giappone 2
MY - Malesia 2
NO - Norvegia 2
TN - Tunisia 2
VN - Vietnam 2
AN - Antille olandesi 1
DK - Danimarca 1
IL - Israele 1
IR - Iran 1
MA - Marocco 1
MK - Macedonia 1
RO - Romania 1
RS - Serbia 1
RU - Federazione Russa 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 4.043
Salva come PNG Salva come JPEG
Città #
Dublin 761
Santa Clara 647
Chandler 363
Singapore 149
Jacksonville 100
Princeton 95
Roxbury 95
New York 91
Beijing 66
Cambridge 50
Naples 49
Medford 48
Bremen 45
Des Moines 33
Boardman 29
Ann Arbor 26
Caserta 26
Wilmington 24
Brussels 22
Ashburn 19
Lappeenranta 18
Nanjing 14
Helsinki 11
Houston 11
Hyderabad 11
Napoli 10
Ercolano 8
Norwalk 8
Sivas 8
Hong Kong 7
Seoul 7
London 6
Milan 6
San Giovanni In Fiore 6
Woodbridge 6
Jinan 5
Munich 5
Falkenstein 4
Frankfurt am Main 4
Menlo Park 4
Nuremberg 4
Shenyang 4
Amsterdam 3
Andover 3
Bari 3
Burbank 3
Casier 3
Duncan 3
Fairfield 3
Giugliano In Campania 3
Hangzhou 3
Hebei 3
Istanbul 3
Los Angeles 3
Montreal 3
Nanchang 3
Ottawa 3
Padova 3
Paris 3
Philadelphia 3
Pune 3
Redwood City 3
São Paulo 3
Taizhou 3
Toronto 3
Vic 3
Acerra 2
Acquafredda 2
Adelfia 2
Bergen 2
Boston 2
Brno 2
Cairo 2
Calgary 2
Camden 2
Capannelle 2
Catamarca 2
Caçador 2
Chiayi County 2
Damietta 2
Dearborn 2
Dishna 2
Dong Ket 2
Eboli 2
Edinburgh 2
Florence 2
Giza 2
Guangzhou 2
Hefei 2
Izmir 2
Karachi 2
Kraków 2
Loreto Aprutino 2
Malang 2
Modugno 2
Monterrey 2
New Taipei City 2
Oristano 2
Palermo 2
Penang 2
Totale 3.045
Salva come PNG Salva come JPEG
Nome #
MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients 90
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 83
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 65
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 65
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 62
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 61
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 59
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 57
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 53
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 53
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: the emerging role of the Cardiomyopathy Team 53
Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest 51
[The COMPASS study] 50
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 50
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 49
Von Willebrand Factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target 49
Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management 49
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 49
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 48
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial 48
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 47
Are we ready for a gender-specific approach in interventional cardiology? 47
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 47
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 46
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 44
Natural history of left ventricular hypertrophy in infants of diabetic mothers 44
Early-onset MINOCA: Prognostic implications and considerations for practice 44
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 43
Mandatory reporting of coronary artery calcifications incidentally noted on chest multi-detector computed tomography: a multicentre experience 43
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: Clinical outcomes at 1-year follow-up 43
Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition 43
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 42
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 42
CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach? 41
Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy 40
Anticoagulation After Primary PCI: The Land of Promises and Uncertainty 40
From Femoral to Radial Approach in Coronary Intervention: Review of the Literature and 6 Years Single-Center Experience 39
Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry 39
Medical treatment of patients with hypertrophic cardiomyopathy: An overview of current and emerging therapy 38
von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications 38
Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up (vol 17, pg 512, 2018) 38
A call for action in bleeding prevention 38
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 38
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 37
Simulation Models of Therapy Intensification in Lipid-Lowering Medicine: Fact or Fantasy? 37
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 36
Cognitive Function in a Randomized Trial of Evolocumab 36
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 36
Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise 36
Clinical significance of family history and bicuspid aortic valve in children and young adult patients with Marfan syndrome 35
Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients with ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial 35
[Evaluation and percutaneous treatment of severely calcified coronary lesions] 35
Prognostic implications of ischemia with nonobstructive coronary arteries (INOCA): Understanding risks for improving treatment 35
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 34
Gender-related differences in changes of estimated bleeding risk in patients on dual antiplatelet therapy: the RE-SCORE multicenter prospective registry 33
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials 33
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease 33
Dual Antiplatelet Therapy Duration in Conservatively Managed Patients with Acute Coronary Syndrome: Any News? 32
Perioperative care of cardiac patient’s candidate for non-cardiac surgery: a critical appraisal of emergent evidence and international guidelines 32
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 32
Letter by Calabro and Gragnano Regarding Article, "Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials" 31
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 31
[Device therapy in chronic heart failure: a case of hypertrophic cardiomyopathy treated with cardiac contractility modulation therapy] 30
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 29
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team 29
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 28
Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial 28
Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and meta-analysis 27
Event recurrence after myocardial infarction: Prediction is very difficult, especially about the future 27
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 27
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 27
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve 27
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 27
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events 26
Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies 26
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 26
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY 26
The benefit and harm of treating STEMI: Between ischemia, bleeding, and reperfusion injury 26
A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation 26
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 26
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives 25
Anti-inflammatory therapies for cardiovascular diseases: novel evidence, clinical implications, and future perspectives 25
Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? 25
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 25
[Gut microbiota and the cardiovascular system: current evidence and future perspectives] 25
Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism 24
Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes 24
Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria 24
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial 24
Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter 24
Physiology-guided revascularization of non-culprit lesions in patients with STEMI: Could vFFR be the way? 23
Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome 23
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease 23
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 22
Predictive ability of longitudinal changes in PRECISE-DAPT score in patients on dual antiplatelet therapy: The RE-SCORE multicentre prospective registry 22
Terapie antitrombotiche in pazienti con infezione da SARS-CoV-2: Dalle attuali evidenze alle ragionevoli raccomandazioni – Position paper del gruppo di studio aterosclerosi, trombosi e biologia vascolare 22
Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology 22
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 22
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 21
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 21
Totale 3.711
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.693
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.693
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020118 0 0 0 0 0 6 39 18 25 15 13 2
2020/2021286 6 0 7 40 33 2 61 11 19 13 62 32
2021/2022784 10 1 8 28 196 11 12 121 21 94 60 222
2022/20231.348 130 74 33 93 123 73 4 70 680 8 27 33
2023/2024743 44 21 23 38 194 110 54 6 7 33 54 159
2024/2025953 7 29 8 77 456 376 0 0 0 0 0 0
Totale 4.486